Partanen J V, Soininen H, Riekkinen P J
Electroencephalogr Clin Neurophysiol. 1986 Jun;63(6):547-51. doi: 10.1016/0013-4694(86)90142-2.
Seventy-seven patients with Alzheimer's disease were submitted to a double-blind no cross-over study of the effect of a synthetic ACTH4-9 analog (Org 2766) on the EEG. The quantitative EEG power spectrum analysis with 22 Org 2766 and 22 placebo treated patients showed no improvement which could be related to the Org 2766 medication (6 months, 40 mg daily), either comparing the successive EEG sessions or comparing the drug treated group with the placebo treated group. The placebo treated group showed a decrease of power in the beta band after 4 and 6 months and an increase of theta after 6 months, which is regarded as a sign of deterioration of the EEG in advancing disease. These changes did not occur in the Org 2766 treated group. However, a subgroup analysis of 9 Org 2766 treated patients and 9 placebo treated patients without other CNS drugs during the study did not reveal consistent differences between the groups after 4 and 6 months of therapy. We believe that Org 2766 does not have a long-term protecting effect on the EEG.
77例阿尔茨海默病患者接受了一项关于合成促肾上腺皮质激素4-9类似物（Org 2766）对脑电图影响的双盲、无交叉研究。对22例接受Org 2766治疗和22例接受安慰剂治疗的患者进行的定量脑电图功率谱分析显示，无论是比较连续的脑电图检查结果，还是比较药物治疗组和安慰剂治疗组，均未发现与Org 2766药物治疗（6个月，每日40 mg）相关的改善。安慰剂治疗组在4个月和6个月后β频段功率降低，6个月后θ频段功率增加，这被视为疾病进展过程中脑电图恶化的迹象。这些变化在Org 2766治疗组中未出现。然而，对9例接受Org 2766治疗和9例接受安慰剂治疗且在研究期间未使用其他中枢神经系统药物的患者进行亚组分析，在治疗4个月和6个月后，两组之间未发现一致的差异。我们认为Org 2766对脑电图没有长期保护作用。
